Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28349988 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL28349987 | 0.91 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL22144554 | 0.90 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL21905394 | 0.90 | ACACB (1.00) | ACACBACACA | |
| SCHEMBL18909873 | 0.90 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL19369286 | 0.90 | ACACB (0.81) | ACACBACACA | |
| SCHEMBL14945396 | 0.87 | ACACB (0.80) | ACACBACACA | |
| SCHEMBL30130074 | 0.87 | ACACB (0.80) | ACACBACACA | |
| SCHEMBL19361566 | 0.87 | ACACA (0.84) | ACACBACACA | |
| SCHEMBL28403880 | 0.86 | ACACB (0.85) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3423456-B1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20200148699-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2020-05-14 | — | — | US | disclosed |
| US-20190225623-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | NIMBUS DISCOVERY, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10183951-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | J.P. LAWSON CONSULTING LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | J.P. LAWSON CONSULTING LLC | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267690-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-20200148699-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-10183951-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-20190225623-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.